Key result
In patients with non-compaction cardiomyopathy, appropriate ICD therapies occurred in 67% over 62 months, and catheter ablation achieved acute procedural success in 9 of 10 patients.
Why the study?
Non-compaction cardiomyopathy is linked to high morbidity and mortality, but knowledge concerning risk stratification, arrhythmogenesis, therapy, and prognosis remains limited.
Does ICD therapy and catheter ablation improve outcomes in patients with non-compaction cardiomyopathy and ventricular arrhythmias?
Observational (n=18)
Yes
Does ICD therapy and catheter ablation improve outcomes in patients with non-compaction cardiomyopathy and ventricular arrhythmias?
ICD therapy and catheter ablation appear to be effective and safe therapeutic options for managing ventricular arrhythmias in patients with non-compaction cardiomyopathy.
Supports ICD/ablation feasibility for VA in non-compaction cardiomyopathy; leaves open randomized confirmation of outcome benefit.
AIMS: Non-compaction cardiomyopathy (NCCM) is associated with high rates of mortality and morbidity. Knowledge regarding risk stratification, arrhythmogenesis, therapy, and prognosis is limited. The aim of this study was to analyse the outcome of patients suffering from NCCM and ventricular arrhythmias (VAs) focusing on a treatment with implantable cardioverter-defibrillator (ICD) therapy and catheter ablation. METHODS AND RESULTS: We conducted a multicentre observational study on 18 patients with NCCM, who underwent ICD implantation for secondary (n = 12) and primary (n = 6) prevention. In patients with multiple symptomatic episodes of VAs catheter ablation was performed. During a follow-up of 62 ± 42 months, 12 patients (67%) presented with appropriate ICD therapies [ventricular tachycardia (VT): n = 8; ventricular fibrillation (VF): n = 4; VT/VF: n = 3]. Ten patients underwent catheter ablation for VT/VF. Solely endocardial ablation was conducted in eight patients, and in two patients endo- and epicardial ablation was performed within the same procedure. Acute procedural success was achieved in 9/10 patients. Ventricular tachycardia recurrence was observed in two patients and the median arrhythmia free interval was 9.5 months (interquartile range 5.3-21 months). One patient underwent reablation, four patients died due to the underlying NCCM, and one patient received a left ventricular assist device. CONCLUSION: Ventricular arrhythmias are common in patients suffering from NCCM and ICD therapy may be effective for primary and secondary prevention. In our cohort, consisting of patients with multiple VA episodes and recurrent ICD therapy, catheter ablation offered a safe and effective therapeutically option.
No takes yet. Share an insight, caveat, or question.
Sohns et al. (2019) conducted an observational in Non-compaction cardiomyopathy (NCCM) and ventricular arrhythmias (n=18). ICD therapy and catheter ablation was evaluated on Appropriate ICD therapies. In patients with non-compaction cardiomyopathy, appropriate ICD therapies occurred in 67% over 62 months, and catheter ablation achieved acute procedural success in 9 of 10 patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: